Replies to post #5928 on Enanta Pharmaceuticals Inc (ENTA)

[dewophile]

GILD earnings this pm show quite the contrast.
US HCV sales decreased in Q4 from 185M to 140 YoY

https://www.gilead.com/news/news-details/2026/gilead-sciences-announces-fourth-quarter-and-full-year-2025-financial-results

ABBV niche approval in acute pts is having a real impact on sales in the chronic patient indication

[DewDiligence]

ABBV’s 1Q26 Mavyret sales=$351M, +9% YoY in_constant_currency:

https://www.prnewswire.com/news-releases/abbvie-reports-first-quarter-2026-financial-results-302757172.html

The geographic breakdown: US $183M, +28% YoY; ex-US $168M, -9% YoY in constant currency.

Clearly, the Mavyret’s approved indication for acute HCV continues to drive growth in the US market.